Compare
Acadia Pharmaceuticals vs Merck & (ACAD vs MRK)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Acadia Pharmaceuticals (ACAD) returned -4.9% and Merck & (MRK) +73.9%; so far this year the figures are -20.5% and +39.4%.
Merck & is the larger company by market value, about 98.6 times the size of Acadia Pharmaceuticals.
On trailing earnings, ACAD trades at 10.0 times and MRK at 149.7 times.
Revenue grew +14.8% at ACAD and +4.9% at MRK over the last year.
ACAD pays no dividend. MRK yields 2.32%.
Data as of the latest close. Not investment advice.
Relative performance
| ACAD | MRK | |
|---|---|---|
| Price | $21.23 | $146.73 |
| 1-day | -0.05% | -0.14% |
| YTD | -20.52% | +39.40% |
| 1 year | -4.93% | +73.87% |
| 3 years | -7.37% | +42.66% |
| Market cap | $3.7B | $361.7B |
| P/E | 10.0 | 149.7 |
| P/S | 3.05 | 5.37 |
| P/B | 2.64 | 8.06 |
| Revenue growth | +14.80% | +4.90% |
| EPS growth | +36.80% | -87.10% |
| Gross margin % | 90.5 | 71.8 |
| Net margin % | 30.1 | 3.6 |
| ROE % | 26.1 | 5.5 |
| Debt / equity | 0.00 | 1.20 |
| FCF yield % | 2.2 | 4.1 |
| Dividend yield % | — | 2.32 |
| Beta | 0.66 | 0.18 |
| RSI (14) | 52.0 | 51.3 |
| Technical rating |